By Denny Jacob
Pharvaris NV shares soared 79%, to $4.50, in early trading after the company said data on PHVS416 demonstrated statistically significant results for treatment of hereditary angioedema, a hereditary condition that causes recurrent swelling.
Top-line data from the Phase 2 study of PHVS416 for the prophylactic treatment of hereditary angioedema is expected in the second half of 2023, said Chief Executive Berndt Modig. Data from the proof-of-concept study is expected to inform the design of expected Phase 3 utilizing PHVS719, an investigational treatment currently in Phase 1 clinical development for hereditary angioedema.
The clinical-stage biopharmaceutical company also said it is continuing to work with the U.S. Food and Drug Administration to resolve holds on clinical trials for PHA121, which the company describes as a competitive antagonist of the bradykinin B2 receptor.
Write to Denny Jacob at email@example.com
(END) Dow Jones Newswires